FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.
Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older.
Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults.
MORE: Despite 'game-changing' new RSV shots, uptake lagged among infants, adults: Experts
More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna.
"RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV."
Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when.
Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk.
The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC.
Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine.
MORE: Respiratory virus activity remains 'high' in US and will 'continue for several more weeks': CDC
As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations.
Instead, it appears Kennedy plans to have the new committee re-discuss the recommendations for RSV vaccination as well as discuss HPV and COVID vaccinations in their meeting scheduled to be held between June 25 and June 27
Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines.
Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine.
FDA expands approval of Moderna's RSV vaccine to some adults under age 60 originally appeared on abcnews.go.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Bacteria in your mouth might reveal how depressed you are, scientists say
Depression could be linked to a lack of diversity in the bacteria in your mouth, according to new research. As you read this, your mouth contains between 500 billion and 1 trillion bacteria. After the gut microbiome, the orifice is the second-largest community of microorganisms in human bodies. Now, researchers at New York University say the makeup of those microbes could be used to help diagnose and treat depression. In a new study, they found that less diversity of microbes in the mouth is associated with the mental health condition. 'It's possible that the oral microbiome influences depressive symptoms through inflammation or changes to the immune system. Conversely, depression can drive changes including dietary intake, poor oral hygiene, increased smoking and drinking, or the use of medications—all of which have the potential to alter the oral microbiome,' Dr. Bei Wu, vice dean for research at NYU Rory Meyers College of Nursing, said in a statement. 'We need more research to understand the direction and underlying pathways of this relationship.' Wu is the senior author of the study, which was published this week in the journal BMC Oral Health. To reach these conclusions, the authors examined data from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey. They used questionnaire data from more than 15,000 adults collected between 2009 and 2012 to compare symptoms of depression with saliva samples. They also used gene sequencing to identify the microbes in the saliva and measure the diversity of the oral microbiome. That's how they found that people with less microbial diversity were more likely to have symptoms of depression. Additional analysis revealed that practices including smoking, drinking, and dental care influenced the relationship between the oral microbiome and depression. They can all change the makeup of bacteria in the mouth. They noted that antidepressants and other psychotropic medications have side effects that can lead to reduced saliva and alter the oral microenvironment. 'Thus, medications not only alleviate depressive symptoms but also have a regulatory effect on oral health,' they said. Still, it remains unclear whether the diversity of microbes in the mouth influences depression, if depression leads to changes in the oral microbiome, or if there's a symbiotic relationship. They noted that a recent study found a potential link between depression and the diversity of bacteria in the gut, and that a growing body of research points to a connection between the oral microbiome and overall health. That's thought to be driven by inflammation and disruptions to the immune system. They hope these findings will support a greater understanding of the issue. In 2021, an estimated 21 million adults had at least one major depressive episode in the past year. 'Having a better understanding of the relationship between the oral microbiome and depression could not only help us learn about the mechanisms underlying depression, but could contribute to the development of new biomarkers or treatments for mood disorders,' said Wu.
Business Insider
5 hours ago
- Business Insider
Capricor treatment of Becker muscular dystrophy granted orphan designation
The FDA granted orphan designation to a treatment of Becker muscular dystrophy being developed by Capricor, according to a post to the agency's website. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
6 hours ago
- Yahoo
Insmed Inc (INSM) Soars 30% on Impressive Study
We recently published a list of . In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other top-performing companies on Tuesday. Insmed Inc. soared by 28.65 percent on Tuesday to close at $90.93 apiece following positive results from the phase 2 trial of its pulmonary arterial hypertension (PAH) treatment, treprostinil palmitil inhalation powder (TPIP). Insmed Incorporated (NASDAQ:INSM) jumped as high as 30 percent at intraday trading following the announcement. According to the company, the phase 2 trial achieved its primary and secondary goals for the treatment of reducing blood pressure in the lungs and improving exercise capacity in patients. Following the results, Insmed Incorporated (NASDAQ:INSM) said it would engage with the Food and Drug Administration (FDA) regarding the phase 3 trial design. The company said it plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of the year, to be followed by a Phase 3 trial in patients in early 2026. A biopharmaceutical research team taking notes in front of a laboratory's microscope. 'These unprecedented Phase 2b results unequivocally demonstrate TPIP's potential to be a highly effective and well-tolerated once-daily prostanoid therapy for the treatment of PAH across disease severities and background treatment regimens. We look forward to expanding upon these results in the upcoming Phase 3 program,' the company said. Overall, INSM ranks 1st on our list of top-performing companies on Tuesday. While we acknowledge the potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
